Study of LY573636-Sodium in Patients With Metastatic Non-Small Cell Lung Cancer

• Status: Completed
• Trial end date: 2008-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective is to estimate the time to progressive disease for patients who receive LY573636-sodium (hereafter referred to as LY573636) after two previous treatments for metastatic non-small cell lung cancer. Patients will receive an intravenous infusion of study drug once every 21 days. Computed tomography (CT)-scans will be done before the first dose and then after every other treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company

Criteria

Inclusion Criteria:

• Diagnosis of metastatic non-small-cell lung cancer

• At least 18 years of age

• Have received 2 previous treatment regimens for metastatic non-small-cell lung cancer

Exclusion Criteria:

• Serious pre-existing medical conditions

• Previous cancer (except skin cancer, excluding melanoma)

• Have received 3 or more previous treatment regimens for metastatic non- small-cell lung cancer

• Active treatment with Coumadin